CAS NO: | 1638-41-1 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
50mg | 电议 |
500mg | 电议 |
p38 MAP Kinase Inhibitor IV is an ATP-competitive inhibitor of p38α/β MAPK with IC50 of 130 nM for p38α and 550 nM for p38β. It is much less active with ≤23% inhibition at 1 μM against p38γ/σ, ERK1/2, and JNK1/2/3. Shown to be more effective than SB 203580 in inhibiting LPS-induced IL-1β release from hPBMC (100% vs. 50% inhibition with 100 μM inhibitor). A recent study showed that p38 MAP Kinase Inhibitor IV could consistently and significantly enhance reprogramming and iPS cell generation from somatic cells. References: Mohetaer M, Li G, Wang Y, Cao L. Protective effects of gemigliptin against type II collagen degradation in human chondrocytes. Biomed Pharmacother. 2018 Aug;104:590-594. doi: 10.1016/j.biopha.2018.04.018. Epub 2018 May 25. PubMed PMID: 29803171.
纯度:≥98%
CAS:1638-41-1